Please scroll down to view our articles and photos. Thank you for your visit.

 
Home Sunburst Store More Health News/Reports About Us
 






JoAnne Green, Founder/Editor,/Publisher
JoAnne Green














New Drug May Protect Against Deadly Effects of Nuclear Radiation 24 Hours After Exposure

photo of summer flowers by JoAnne Green

An interdisciplinary research team led by The University of Texas Medical Branch at Galveston reports a new breakthrough in countering the deadly effects of radiation exposure. A single injection of a regenerative peptide was shown to significantly increase survival in mice when given 24 hours after nuclear radiation exposure. The study currently appears in Laboratory Investigation, a journal in the Nature Publishing group.

UTMB lead author Carla Kantara, postdoctoral fellow in biochemistry and molecular biology, said that a single injection of the investigative peptide drug TP508 given 24 hours after a potentially-lethal exposure to radiation appears to significantly increase survival and delay mortality in mice by counteracting damage to the gastrointestinal system.

The threat of a nuclear incident, with the potential to kill or injure thousands of people, has raised global awareness about the need for medical countermeasures that can prevent radiation-induced bodily damage and keep people alive, even if given a day or more after contact with nuclear radiation.

Exposure to high doses of radiation triggers a number of potentially lethal effects. Among the most severe of these effects is the gastrointestinal, or GI, toxicity syndrome that is caused by radiation-induced destruction of the intestinal lining. This type of GI damage decreases the ability of the body to absorb water and causes electrolyte imbalances, bacterial infection, intestinal leakage, sepsis and death.

The GI toxicity syndrome is triggered by radiation-induced damage to crypt cells in the small intestines and colon that must continuously replenish in order for the GI tract to work properly. Crypt cells are especially susceptible to radiation damage and serve as an indicator of whether someone will survive after total body radiation exposure.

"The lack of available treatments that can effectively protect against radiation-induced damage has prompted a search for countermeasures that can minimize the effects of radiation after exposure, accelerate tissue repair in radiation-exposed individuals and increase the chances for survival following a nuclear event," said Darrell Carney, UTMB adjunct professor in biochemistry and molecular biology and CEO of Chrysalis BioTherapeutics, Inc. "Because radiation-induced damage to the intestines plays such a key role in how well a person recovers from radiation exposure, it's crucial to develop novel medications capable of preventing GI damage."

The peptide drug TP508 was developed for use in stimulating repair of skin, bone and muscle tissues. It has previously been shown to begin tissue repair by stimulating proper blood flow, reducing inflammation and reducing cell death. In human clinical trials, the drug has been reported to increase healing of diabetic foot ulcers and wrist fractures with no drug-related adverse events.

"The current results suggest that the peptide may be an effective emergency nuclear countermeasure that could be delivered within 24 hours after exposure to increase survival and delay mortality, giving victims time to reach facilities for advanced medical treatment," Kantara said.











Click here to like us on Facebook.
Click here to like us on Facebook.





Most Viewed Articles

Walking May Help Protect Kidney Patients Against Heart Disease and Infections

Food Helps Older Generation Age Successfully

Cosmetic Treatment Can Open the Door to Bacteria

Food Allergy Nearly Doubles Among Black Children
 
How bacteria communicate with us to build a special relationship

Vegetables Can Make You Look Like a Hero, and a Better Cook

Promising Cervical Cancer Study

Better Broccoli, Enhanced Anti-Cancer Benefits with Longer Shelf Life




 



 
Home  More News/Reports Sunburst Store About Us Privacy Pledge Terms of Use Site Map

Copyright © 2017 Sunburst Worldwide Enterprises. All rights reserved.
Warning: All of the pages on this site are protected under U.S. and International Copyright laws.
Reproduction by any means or for any purpose is not allowed without the express written permission of the copyright owner.
SunburstGlobalHealthNews.com is an online publication of Sunburst Worldwide Enterprises.
By using this website, you agree to our Terms of Use.